Login to Your Account



Other News To Note


Tuesday, March 20, 2012
• MabCure Inc., of New York, said it entered an agreement with the City University of New York Center for Advanced Technology to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents. Terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription